Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Harvard Business School
Boehringer Ingelheim
UBS
Accenture
Healthtrust
Daiichi Sankyo
Cantor Fitzgerald
Farmers Insurance

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,947,295

« Back to Dashboard

Which drugs does patent 7,947,295 protect, and when does it expire?

Patent 7,947,295 protects ILEVRO and is included in one NDA.

This patent has thirty-six patent family members in fifteen countries.
Summary for Patent: 7,947,295
Title:Ophthalmic compositions containing a synergistic combination of two polymers
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
Inventor(s): Chowhan; Masood A. (Arlington, TX), Chen; Huagang (Arlington, TX)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:11/673,070
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,947,295
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 7,947,295

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,947,295

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,709,012 Ophthalmic compositions containing a synergistic combination of two polymers ➤ Try a Free Trial
8,313,754 Ophthalmic compositions containing a synergistic combination of two polymers ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,947,295

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004249137 ➤ Try a Free Trial
Australia 2010200297 ➤ Try a Free Trial
Australia 2012205283 ➤ Try a Free Trial
Brazil PI0411361 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Queensland Health
AstraZeneca
Dow
Boehringer Ingelheim
Cerilliant
Farmers Insurance
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.